Nasdaq · Healthcare
Vericel Corp (VCEL)
As-reported financials and recent SEC filings for Vericel Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$276.3M
Net income
$16.5M
Net margin
6.0%
Diluted EPS
$0.32
ROE
4.7%
P/E (TTM)
107.5×
Market cap
$2.36B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $276.3M | $237.2M | $197.5M | $163.7M | $153.1M |
| Gross profit | $205.6M | $172.1M | $135.6M | $109.1M | $102.9M |
| Operating income | $11.0M | $4.5M | $-6.5M | $-17.1M | $-7.9M |
| Net income | $16.5M | $10.4M | $-3.2M | $-16.7M | $-7.5M |
| Diluted EPS | $0.32 | $0.20 | $-0.07 | $-0.35 | $-0.16 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →1442026-06-18
View on EDGAR →1442026-06-18
View on EDGAR →Go deeper on VCEL
Search Vericel Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.